Neuroacanthocytosis

Handbook of Clinical Neurology

Volumn 100, Issue , 2011, Pages 141-151

  Walker, Ruth H ^a   Jung, Hans H ^b   Danek, Adrian ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOOK; CEREBELLUM; GENETICS; HEMATOLOGY; HUMAN; HUNTINGTON CHOREA; NEUROACANTHOCYTOSIS; NEUROMUSCULAR SYNAPSE; PATHOLOGY;

CEREBELLUM; HEMATOLOGY; HUMANS; HUNTINGTON DISEASE; NEUROACANTHOCYTOSIS; NEUROMUSCULAR JUNCTION;

EID: 79954494221     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52014-2.00007-0     Document Type: Book

References (110)

1. Al-Asmi A., Jansen A.C., Badhwar A., et al. Familial temporal lobe epilepsy as a presenting feature of choreoacanthocytosis. Epilepsia 2005, 46:1256-1263.
2. Allen F.H., Krabbe S.M., Corcoran P.A. A new phenotype (McLeod) in the Kell blood-group system. Vox Sang 1961, 6:555-560.
3. Aminoff M.J. Acanthocytosis and neurological disease. Brain 1972, 95:749-760.
4. Anonymous Nervous disorders and thorn cells. Br Med J 1971, 1:683-684.
5. Bader B., Velayos-Baeza A., Walker R.H., et al. Dominant transmission of chorea-acanthocytosis with VPS13A mutations remains speculative. Acta Neuropathol 2009, 117:95-96.
6. Bardien S., Abrahams F., Soodyall H., et al. A South African mixed ancestry family with Huntington disease-like 2: Clinical and genetic features. Mov Disord 2007, 22:2083-2089.
7. Bauer I., Gencik M., Laccone F., et al. Trinucleotide repeat expansions in the junctophilin-3 gene are not found in Caucasian patients with a Huntington's disease-like phenotype. Ann Neurol 2002, 51:662.
8. Bayreuther C., Borg M., Ferrero-Vacher C., et al. Choreo-acanthocytose sans acanthocytes. Revue Neurologique 2010, 166:100-103.
9. Bosman G.J., Bartholomeus I.G., De Grip W.J., et al. Erythrocyte anion transporter and antibrain immunoreactivity in chorea-acanthocytosis. A contribution to etiology, genetics, and diagnosis. Brain Res Bull 1994, 33:523-528.
10. Bosman G.J.C.G.M., Walker R.H. Acanthocytosis-related changes in erythrocyte band 3: Clues for a mechanism and inspiration for future research. Mov Disord 2005, 20:1675.
11. Bostantjopoulou S., Katsarou Z., Kazis A., et al. Neuroacanthocytosis presenting as parkinsonism. Mov Disord 2000, 15:1271-1273.
12. Brin M.F., Hays A., Symmans W.A., et al. Neuropathology of McLeod phenotype is like chorea-acanthocytosis (CA). Can J Neurol Sci 1993, 20:234.
13. Bruneau M.A., Lesperance P., Chouinard S. Schizophrenia-like presentation of neuroacanthocytosis. J Neuropsychiatry Clin Neurosci 2003, 15:378-380.
14. Burbaud P. Deep brain stimulation in neuroacanthocytosis. Mov Disord 2005, 20:1681-1682.
15. Burbaud P., Rougier A., Ferrer X., et al. Improvement of severe trunk spasms by bilateral high-frequency stimulation of the motor thalamus in a patient with chorea-acanthocytosis. Mov Disord 2002, 17:204-207.
16. Burbaud P., Vital A., Rougier A., et al. Minimal tissue damage after stimulation of the motor thalamus in a case of chorea-acanthocytosis. Neurology 2002, 59:1982-1984.
17. Cavalli G., de Gregorio C., Nicosia S., et al. Coinvolgimento cardiaco nella coreo-acantocitosi amiotrofica familiare: descrizione di due nuovi casi clinici. Ann Ital Med Int 1995, 10:249-252.
18. Chatterjee A., Frucht S.J. Tetrabenazine in the treatment of severe pediatric chorea. Mov Disord 2003, 18:703-706.
19. Ching K.H.L., Westaway S.K., Gitschier J., et al. HARP syndrome is allelic with pantothenate kinase-associated neurodegeneration. Neurology 2002, 58:1673-1674.
20. Claperon A., Hattab C., Armand V., et al. The Kell and XK proteins of the Kell blood group are not co-expressed in the central nervous system. Brain Res 2007, 1147:12-24.
21. Clark M.R., Aminoff M.J., Chiu D.T., et al. Red cell deformability and lipid composition in two forms of acanthocytosis: enrichment of acanthocytic populations by density gradient centrifugation. J Lab Clin Med 1989, 113:469-481.
22. Critchley E.M., Clark D.B., Wikler A. Acanthocytosis and neurological disorder without betalipoproteinemia. Arch Neurol 1968, 18:134-140.
23. Danek A., Rubio J.P., Rampoldi L., et al. McLeod neuroacanthocytosis: genotype and phenotype. Ann Neurol 2001, 50:755-764.
24. Danek A., Tison F., Rubio J., et al. The chorea of McLeod syndrome. Mov Disord 2001, 16:882-889.
25. Dobson-Stone C., Danek A., Rampoldi L., et al. Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis. Eur J Hum Genet 2002, 10:773-781.
26. Dobson-Stone C., Velayos-Baeza A., Filippone L.A., et al. Chorein detection for the diagnosis of chorea-acanthocytosis. Ann Neurol 2004, 56:299-302.
27. Dydak U., Mueller S., Sandor P.S., et al. Cerebral metabolic alterations in McLeod syndrome. Eur Neurol 2006, 56:17-23.
28. Fontenelle L.F., Leite M.A. Treatment-resistant self-mutilation, tics, and obsessive-compulsive disorder in neuroacanthocytosis: a mouth guard as a therapeutic approach. J Clin Psychiatry 2008, 69:1186-1187.
29. Gandhi S., Hardie R.J., Lees A.J. An update on the Hardie neuroacanthocytosis series. Neuroacanthocytosis Syndromes II 2008, 43-51. Springer-Verlag, Berlin. R.H. Walker, A. Saiki, A. Danek (Eds.).
30. Geser F., Tolnay M., Jung H.H. The Neuropathology of McLeod Syndrome. Neuroacanthocytosis Syndromes II 2008, 197-203. Springer-Verlag, Berlin. R.H. Walker, A. Saiki, A. Danek (Eds.).
31. Ghorayeb I., Dolenc-Groselj L., Kobal J., et al. Sleep disorders in neuroacanthocytosis. Neuroacanthocytosis Syndromes II 2009, 249-253. Springer, Berlin. R.H. Walker, A. Saiki, A. Danek (Eds.).
32. Gradstein L., Danek A., Grafman J., et al. Eye movements in chorea-acanthocytosis. Invest Ophthalmol Vis Sci 2005, 46:1979-1987.
33. Greenstein P.E., Vonsattel J.P., Margolis R.L., et al. Huntington's disease like-2 neuropathology. Mov Disord 2007, 22:1416-1423.
34. Gregory A., Polster B.J., Hayflick S.J. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet 2009, 46:73-80.
35. Gupta F., Chan N., Alterman R., et al. DBS frequency screening for programming optimization in a patient with chorea-acanthocytosis. Mov Disord 2009, 23:S384.
36. Hardie R.J., Pullon H.W., Harding A.E., et al. Neuro-acanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain 1991, 114:13-49.
37. Hartig M.B., Hortnagel K., Garavaglia B., et al. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann Neurol 2006, 59:248-256.
38. Hayflick S.J., Westaway S.K., Levinson B., et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 2003, 348:33-40.
39. Hebb M.O., Garcia R., Gaudet P., et al. Bilateral stimulation of the globus pallidus internus to treat choreathetosis in Huntington's disease: technical case report. Neurosurgery 2006, 58:E383.
40. Henkel K., Danek A., Grafman J., et al. Head of the caudate nucleus is most vulnerable in chorea-acanthocytosis: a voxel-based morphometry study. Mov Disord 2006, 21:1728-1731.
41. Hewer E., Danek A., Schoser B.G., et al. McLeod myopathy revisited - more neurogenic and less benign. Brain 2007, 130:3285-3296.
42. Holmes S.E., O'Hearn E., Rosenblatt A., et al. A repeat expansion in the gene encoding junctophilin-3 is associated with Huntington disease-like 2. Nat Genet 2001, 29:377-378.
43. Ho M.F., Chelly J., Carter N., et al. Isolation of the gene for McLeod syndrome that encodes a novel membrane-transport protein. Cell 1994, 77:869-880.
44. Houlden H., Lincoln S., Farrer M., et al. Compound heterozygous PANK2 mutations confirm HARP and Hallervorden-Spatz syndromes are allelic. Neurology 2003, 61:1423-1426.
45. Huppertz H.J., Kroll-Seger J., Danek A., et al. Automatic striatal volumetry allows for identification of patients with chorea-acanthocytosis at single subject level. J Neural Transm 2008, 115:1393-1400.
46. Ichiba M., Nakamura M., Kusumoto A., et al. Clinical and molecular genetic assessment of a chorea-acanthocytosis pedigree. J Neurol Sci 2007, 263:124-132.
47. Jung H.H., Brandner S. Malignant mcleod myopathy. Muscle Nerve 2002, 26:424-427.
48. Jung H.H., Haker H. Schizophrenia as a manifestation of X-linked McLeod-neuroacanthocytosis syndrome. J Clin Psychiatry 2004, 65:722-723.
49. Jung H.H., Hergersberg M., Kneifel S., et al. McLeod syndrome: a novel mutation, predominant psychiatric manifestations, and distinct striatal imaging findings. Ann Neurol 2001, 49:384-392.
50. Jung H.H., Russo D., Redman C., et al. Kell and XK immunohistochemistry in McLeod myopathy. Muscle Nerve 2001, 24:1346-1351.
51. Kageyama Y., Matsumoto K., Ichikawa K., et al. A new phenotype of chorea-acanthocytosis with dilated cardiomyopathy and myopathy. Mov Disord 2007, 22:1669-1670.
52. Katsube T., Shimono T., Ashikaga R., et al. Demonstration of cerebellar atrophy in neuroacanthocytosis of 2 siblings. AJNR Am J Neuroradiol 2009, 30:386-388.
53. Kay M.M.B., Bosman G.J.C.G.M., Lawrence C. Functional topography of band 3: specific structural alteration linked to functional aberrations in human erythrocytes. Proc Natl Acad Sci U S A 1988, 85:492-496.
54. Kenney C., Hunter C., Davidson A., et al. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord 2006, 22:10-13. 2007.
55. Kihara M., Nakashima H., Taki M., et al. A case of chorea-acanthocytosis with dysautonomia; quantitative autonomic deficits using CASS. Auton Neurosci 2002, 97:42-44.
56. Klempir J., Roth J., Zarubova K., et al. The McLeod syndrome without acanthocytes. Parkinsonism Relat Disord 2008, 14:364-366.
57. Lee S. Molecular basis of Kell blood group phenotypes. Vox Sang 1997, 73:1-11.
58. Lee S., Russo D., Redman C.M. The Kell blood group system: Kell and XK membrane proteins. Semin Hematol 2000, 37:113-121.
59. Lee S., Sha Q., Wu X., et al. Expression profiles of mouse Kell, XK, and XPLAC mRNA. J Histochem Cytochem 2007, 55:365-374.
60. Levine I.M. An hereditary neurologic disease with acanthocytosis. Neurology 1964, 14:272.
61. Lin F.C., Wei L.J., Shih P.Y. Effect of levetiracetam on truncal tic in neuroacanthocytosis. Acta Neurol Taiwan 2006, 15:38-42.
62. Lossos A., Dobson-Stone C., Monaco A.P., et al. Early clinical heterogeneity in choreoacanthocytosis. Arch Neurol 2005, 62:611-614.
63. Magazi D.S., Krause A., Bonev V., et al. Huntington's disease: genetic heterogeneity in black African patients. S Afr Med J 2008, 98:200-203.
64. Malandrini A., Cesaretti S., Mulinari M., et al. Acanthocytosis, retinitis pigmentosa, pallidal degeneration. Report of two cases without serum lipid abnormalities. J Neurol Sci 1996, 140:129-131.
65. Margolis R.L., O'Hearn E., Rosenblatt A., et al. A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion. Ann Neurol 2001, 50:373-380.
66. Margolis R.L., Holmes S.E., Rosenblatt A., et al. Huntington's disease-like 2 (HDL2) in North America and Japan. Ann Neurol 2004, 56:670-674.
67. McIntosh J. Multidisciplinary neurorehabilitation in chorea-acanthocytosis; A case study 2008, 271-284. Neuroacanthocytosis Syndromes II. Springer-Verlag, Berlin. R.H. Walker, S. Saiki, A. Danek (Eds.).
68. * and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 2008, 70:1614-1619.
69. Moro E., Lang A.E., Strafella A.P., et al. Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol 2004, 56:290-294.
70. Moss J.H., Stewart D.E. Iatrogenic parkinsonism in Huntington's chorea. Can J Psychiatry 1986, 31:865-866.
71. Mukoyama M., Kazui H., Sunohara N., et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes with acanthocytosis: a clinicopathological study of a unique case. J Neurol 1986, 233:228-232.
72. Müller-Vahl K.R., Berding G., Emrich H.M., et al. Chorea-acanthocytosis in monozygotic twins: clinical findings and neuropathological changes as detected by diffusion tensor imaging, FDG-PET and (123)I-beta-CIT-SPECT. J Neurol 2007, 254:1081-1088.
73. Nishi M., Hashimoto K., Kuriyama K., et al. Motor discoordination in mutant mice lacking junctophilin type 3. Biochem Biophys Res Commun 2002, 292:318-324.
74. Oechslin E., Kaup D., Jenni R., et al. Cardiac abnormalities in McLeod syndrome. Int J Cardiol 2007, 132:130-132. 2009.
75. Oechsner M., Buchert R., Beyer W., et al. Reduction of striatal glucose metabolism in McLeod choreoacanthocytosis. J Neurol Neurosurg Psychiatry 2001, 70:517-520.
76. Ondo W.G., Tintner R., Thomas M., et al. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharm 2002, 25:300-302.
77. Orrell R.W., Amrolia P.J., Heald A., et al. Acanthocytosis, retinitis pigmentosa, and pallidal degeneration: a report of three patients, including the second reported case with hypoprebetalipoproteinemia (HARP syndrome). Neurology 1995, 45:487-492.
78. Pearson S.J., Reynolds G.P. Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease. Neuropharmacology 1988, 27:717-719.
79. Pellecchia M.T., Valente E.M., Cif L., et al. The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration. Neurology 2005, 64:1810-1812.
80. Rampoldi L., Dobson-Stone C., Rubio J.P., et al. A conserved sorting-associated protein is mutant in chorea-acanthocytosis. Nat Genet 2001, 28:119-120.
81. Rampoldi L., Danek A., Monaco A.P. Clinical features and molecular bases of neuroacanthocytosis. J Mol Med 2002, 80:475-491.
82. Rodrigues G.G., Walker R.H., Brice A., et al. Huntington's disease-like 2 in Brazil - Report of 4 patients. Mov Disord 2008, 23:2244-2247.
83. Rubio J.P., Danek A., Stone C., et al. Chorea-acanthocytosis: genetic linkage to chromosome 9q21. Am J Hum Genet 1997, 61:899-908.
84. Rudnicki D.D., Holmes S.E., Lin M.W., et al. Huntington's disease-like 2 is associated with CUG repeat-containing RNA foci. Ann Neurol 2007, 61:272-282.
85. Rudnicki D.D., Pletnikova O., Vonsattel J.P., et al. A comparison of Huntington disease and Huntington disease-like 2 neuropathology. J Neuropathol Exp Neurol 2008, 67:366-374.
86. Russo D., Lee S., Redman C. Intracellular assembly of Kell and XK blood group proteins. Biochim Biophys Acta 1999, 1461:10-18.
87. Saiki S., Hirose G., Sakai K., et al. Chorea-acanthocytosis associated with Tourettism. Mov Disord 2004, 19:833-836.
88. Santos C., Wanderley H., Vedolin L., et al. Huntington disease-like 2: the first patient with apparent European ancestry. Clin Genet 2008, 73:480-485.
89. Scheid R., Bader B., Ott D.V., et al. Development of mesial temporal lobe epilepsy in chorea-acanthocytosis. Neurology 2009, 73:1419-1422.
90. Silvestri R., Raffaele M., De Domenico P., et al. Sleep features in Tourette's syndrome, neuroacanthocytosis and Huntington's chorea. Neurophysiol Clin 1995, 25:66-77.
91. Stanfield G.M., Horvitz H.R. The ced-8 gene controls the timing of programmed cell deaths in C. Elegans. Mol Cell 2000, 5:423-433.
92. Stevanin G., Fujigasaki H., Lebre A.S., et al. Huntington's disease-like phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genes. Brain 2003, 126:1599-1603.
93. Storch A., Brockmann K., Pekrun A. Familial acanthocytosis with paroxysmal exertion-induced dyskinesias and epilepsy (FAPED). Aktuel Neurol 2004, 31:P446.
94. Storch A., Kornhass M., Schwarz J. Testing for acanthocytosis - A prospective reader-blinded study in movement disorder patients. J Neurol 2005, 252:84-90.
95. Thomas M., Jankovic J. Neuroacanthocytosis. Neurological Therapeutics: Principles and Practice 2006, 2882-2889. Informa Healthcare. Milton Park, Abingdon, Oxon, UK. J.H. Noseworthy (Ed.).
96. Tsai C.H., Chen R.S., Chang H.C., et al. Acanthocytosis and spinocerebellar degeneration: a new association?. Mov Disord 1997, 12:456-459.
97. Tschopp L., Raina G., Salazar Z., et al. Neuroacanthocytosis and carbamazepine responsive paroxysmal dyskinesias. Parkinsonism Relat Disord 2008, 14:440-442.
98. Ueno S., Maruki Y., Nakamura M., et al. The gene encoding a newly discovered protein, chorein, is mutated in chorea-acanthocytosis. Nat Genet 2001, 28:121-122.
99. Velayos-Baeza A., Levecque C., Dobson-Stone C., et al. The function of chorein 2008, 87-105. Neuroacanthocytosis Syndromes II. Springer, Berlin. R.H. Walker, S. Saiki, A. Danek (Eds.).
100. Walker R.H., Morgello S., Davidoff-Feldman B., et al. Autosomal dominant chorea-acanthocytosis with polyglutamine-containing neuronal inclusions. Neurology 2002, 58:1031-1037.
101. Walker R.H., Jankovic J., O'Hearn E., et al. Phenotypic Features of Huntington Disease-like 2. Mov Disord 2003, 18:1527-1530.
102. Walker R.H., Rasmussen A., Rudnicki D., et al. Huntington's Disease-like 2 can present as chorea-acanthocytosis. Neurology 2003, 61:1002-1004.
103. Walker R.H., Liu Q., Ichiba M., et al. Self-mutilation in chorea-acanthocytosis - manifestation of movement disorder or psychopathology?. Mov Disord 2006, 21:2268-2269.
104. Walker R.H., Jung H.H., Tison F., et al. Phenotypic variation among brothers with the McLeod neuroacanthocytosis syndrome. Mov Disord 2007, 22:244-248.
105. Walterfang M., Yucel M., Walker R., et al. Adolescent obsessive compulsive disorder heralding chorea-acanthocytosis. Mov Disord 2008, 23:422-425.
106. Weber Y.G., Storch A., Wuttke T.V., et al. GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. J Clin Invest 2008, 118:2157-2168.
107. Wihl G., Volkmann J., Allert N., et al. Deep brain stimulation of the internal pallidum did not improve chorea in a patient with neuro-acanthocytosis. Mov Disord 2001, 16:572-575.
108. Wild E.J., Mudanohwo E.E., Sweeney M.G., et al. Huntington's disease phenocopies are clinically and genetically heterogeneous. Mov Disord 2008, 23:716-720.
109. Yianni J., Nandi D., Bradley K., et al. Senile chorea treated by deep brain stimulation: a clinical, neurophysiological and functional imaging study. Mov Disord 2004, 19:597-602.
110. Zhou B., Westaway S.K., Levinson B., et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001, 28:345-349.